Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
Status:
Completed
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
Participants in this study will receive two treatments, placebo and ERX-963, on different
days in a randomized fashion.
The primary purpose of this study is to investigate the safety and tolerability of ERX-963 in
participants diagnosed with Myotonic Dystrophy, Type 1 (DM1).
The secondary purpose is to evaluate the potential of ERX-963 treatment to reduce excessive
daytime sleepiness / hypersomnia and improve cognitive function in DM1 participants compared
to placebo treatment.